Blar i NTNU Open på forfatter "Ochando, Jordi"

Viser treff 1-3 av 3

    • Cyclic Arginine–Glycine–Aspartate-Decorated Lipid Nanoparticle Targeting toward Inflammatory Lesions Involves Hitchhiking with Phagocytes 

      Sofias, Alexandros Marios; Bjørkøy, Geir; Ochando, Jordi; Sønstevold, Linda; Hegvik, Maria; Davies, Catharina de Lange; Haraldseth, Olav; Lammers, Twan; Mulder, Willem J. M.; Hak, Sjoerd (Peer reviewed; Journal article, 2021)
      Active-targeting nanomedicine formulations have an intricate in vivo behavior. Nanomedicines developed to target endothelial αvβ3-integrin are recently demonstrated to display extensive uptake by circulating phagocytes. ...

    • Systematically evaluating DOTATATE and FDG as PET immuno-imaging tracers of cardiovascular inflammation 

      Toner, Yohana C.; Ghotbi, Adam A.; Naidu, Sonum; Sakurai, Ken; van Leent, Mandy M. T.; Jordan, Stefan; Ordikhani, Farideh; Amadori, Letizia; Sofias, Alexandros Marios; Fisher, Elizabeth L.; Maier, Alexander; Sullivan, Nathaniel; Munitz, Jazz; Senders, Max L.; Mason, Christian; Reiner, Thomas; Soultanidis, Georgios; Tarkin, Jason M.; Rudd, James H. F.; Giannarelli, Chiara; Ochando, Jordi; Pérez-Medina, Carlos; Kjaer, Andreas; Mulder, Willem J. M.; Fayad, Zahi A.; Calcagno, Claudia (Peer reviewed; Journal article, 2022)
      In recent years, cardiovascular immuno-imaging by positron emission tomography (PET) has undergone tremendous progress in preclinical settings. Clinically, two approved PET tracers hold great potential for inflammation ...

    • Tumor Targeting by αvβ3-Integrin-Specific Lipid Nanoparticles Occurs via Phagocyte Hitchhiking 

      Sofias, Alexandros Marios; Toner, Yohana C.; Meerwaldt, Anu E.; van Leent, Mandy M. T.; Soultanidis, Georgios; Elschot, Mattijs; Gonai, Haruki; Grendstad, Kristin; Flobak, Åsmund; Neckmann, Ulrike; Wolowczyk, Camilla; Fisher, Elizabeth L.; Reiner, Thomas; Davies, Catharina de Lange; Bjørkøy, Geir; Teunissen, Abraham J. P.; Ochando, Jordi; Pérez-Medina, Carlos; Mulder, Willem J. M.; Hak, Sjoerd (Journal article; Peer reviewed, 2020)
      Although the first nanomedicine was clinically approved more than two decades ago, nanoparticles’ (NP) in vivo behavior is complex and the immune system’s role in their application remains elusive. At present, only ...